Search results: (10000)
News Diabetic Nephropathy and COVID-19: Fatal Connection?
People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus – angiotensin-converting enzyme 2 (ACE2).
News Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).
News Current Results of Brigatinib in the Treatment of Lung Cancer
The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.
News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics – Results of a Large Meta-Analysis
Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
News Impact of Physiotherapy and Sports Activities on the Results of Movement Tests in Children with Hemophilia
At the 9th Hemophilia Academy, held online from October 5-7 in Budapest, a lecture by Mgr. Marie Katzerová from University Hospital Brno titled “Physiotherapy, Sports, and Hemophilia” aimed to elucidate the impact of physical activity on the results of movement tests in children with hemophilia.
News Clinical Experiences with Reversing Dabigatran with Idarucizumab
Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.
News Real Impact of Lockdown on Asthma Treatment – EAACI Survey Results
Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment of chronic diseases such as asthma. A study published in the journal Allergy focused on evaluating treatment approaches for adult and pediatric patients with asthma during the coronavirus pandemic lockdowns.
News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice
Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.
News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?
The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.
News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
News Efficacy and Safety of Enoxaparin as Bridging Anticoagulant Therapy After Ventricular Assist Device Implantation
The implantation of a ventricular assist device has become an increasingly common method in the treatment of end-stage heart failure in recent years. The implantation of the device necessitates anticoagulant therapy. In the long term, warfarin is most often used according to guidelines, but there are no clear recommendations for early postoperative anticoagulant therapy. The aim of a clinical study published last year was to evaluate the efficacy and safety of enoxaparin as bridging anticoagulant therapy after device implantation within a 3-month postoperative period.
News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment
The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.
News Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC
Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis presented below compared the efficacy and safety of gefitinib in combination with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC.
News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic
In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).
News Evaluation of Treatment Response in CLL
The size of lymph nodes, liver, spleen, blood cell counts, systemic symptoms... Changes in these indicators provide clear information on whether the disease of chronic lymphocytic leukemia (CLL) has progressed, stabilized, or if the patient has achieved partial or complete remission after therapy. An even deeper insight into what has happened at the cellular level in the human body is provided by the evaluation of minimal residual disease (MRD). Why is it meaningful to search for the remaining leukemic cells? How to identify them, in what material, and when? And is the information about MRD truly useful for all types and lines of treatment? The answers to these questions, along with other current data and information on the topic, are brought by the following presentation.
News Does the emergence of resistance to cetuximab mean ineffectiveness of all anti-EGFR antibodies?
Colorectal cancer (CRC) cells respond to targeted therapy in different ways. Besides the desired outcome of cell death, CRC cells can adapt and survive through changes in their genome. It is important to recognize that the developed resistance to targeted therapy may, but does not necessarily, apply uniformly across a class of drugs or a single mechanism of action.
News Final Analysis of the STASEY Study: How Did Emicizumab Fare in the Prophylaxis of Hemophilia A Patients with FVIII Inhibitors?
The July virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021 offered a variety of interesting topics. Among the poster presentations, data from the multicenter, single-arm, open-label phase III STASEY clinical trial, which evaluated the safety and tolerability of emicizumab prophylaxis in patients with hemophilia A and an FVIII inhibitor, were included. The results were presented on behalf of an international team of authors by Víctor Jiménez-Yuste from the University Hospital La Paz in Madrid.
News Basic Cardiovascular Benefits of the Oral Antidiabetic Medication Empagliflozin
Type 2 diabetes mellitus is one of the main risk factors for cardiovascular (CV) diseases. Empagliflozin is among the modern oral antidiabetic medications, and in 2015 it became a pioneer among diabetes treatments shown to reduce the incidence of major CV events. It has also been proven to reduce the risk of hospitalization for heart failure.
News Reversal of Dabigatran Effects with Idarucizumab in Patients Requiring Urgent Procedures: Subanalysis of the RE-VERSE AD Study
The effect of idarucizumab as a reversal agent in patients treated with dabigatran in situations requiring urgent surgery or other invasive procedures was evaluated in a subanalysis from the RE-VERSE AD study published in 2021.
News Comparable Long-term Safety of Tofacitinib and Biologics in RA Treatment – Data from a US Registry
An analysis of the long-term safety profile of tofacitinib in real clinical practice was published in the journal of the American College of Rheumatology (ACR). Patients with rheumatoid arthritis (RA) who started treatment with tofacitinib showed a similar frequency of predefined adverse events of special interest compared to a cohort treated with biological disease-modifying antirheumatic drugs (bDMARDs).
News HAE Junior Helps Improve the Quality of Life for Pediatric Patients
Living with hereditary angioedema (HAE) brings chronic health issues, long-term psychological stress, and a lifelong threat of death. Initial symptoms of HAE appear during childhood or adolescence. Many patients, however, remain misdiagnosed for a long time. The patient organization HAE Junior strives for a better quality of life for patients with this condition by improving awareness and access to modern therapy.
News Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A is not always simple. An interesting perspective and recommendations are provided by a model analysis assessing the cost and effectiveness of individual available preparations.
News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).
News Efficacy and Safety of Dupilumab in the Treatment of Atopic Dermatitis in Adolescents
In the pediatric population, atopic dermatitis (AD) has a relatively high prevalence, but therapeutic options are often limited. The following article offers a summary of the results from a clinical study published last year focusing on the efficacy and safety of dupilumab in adolescent patients with moderate to severe AD that is not adequately controlled by topical therapy.
News Association between Cardiovascular Risk Factors and Cognitive Disorders in Patients with Schizophrenia
Schizophrenia is a disease characterized by a certain degree of cognitive impairment, but also an increased risk of cardiovascular diseases, which are often the cause of deteriorating cognitive functions in the general population. The aim of a large meta-analysis was to elucidate the association between cardiovascular risk factors and cognitive disorders in patients with schizophrenia and schizoaffective disorder, based on the results of a previous smaller study that demonstrated an association between metabolic syndrome, diabetes, and cognitive disorders.